Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fausto Castagnetti

Showing results (41-50 of 158) with videos related to

Pageof 16
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 22, 2013
Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemiaMario Arpinati, Giulia Tolomelli, Maria Teresa Bochicchio, et al.
Mycoses|September 6, 2017
Successful treatment of bilateral endogenous Fusarium solani endophthalmitis in a patient with acute lymphocytic leukaemiaIlaria Rizzello, Fausto Castagnetti, Pier Giorgio Toschi, et al.
Cells|July 14, 2023
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel InsightsMiriam Iezza, Sofia Cortesi, Emanuela Ottaviani, et al.
Plos One|July 7, 2015
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid LeukemiaManuela Mancini, Elisa Leo, Ken-Ichi Takemaru, et al.
Journal of Cancer Research and Clinical Oncology|January 14, 2017
No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinibMarkus Pfirrmann, Dobromira Evtimova, Susanne Saussele, et al.
Frontiers in Oncology|August 22, 2022
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitorsManuela Mancini, Sara De Santis, Cecilia Monaldi, et al.
Hematological Oncology|January 29, 2020
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axisManuela Mancini, Sara De Santis, Cecilia Monaldi, et al.
Leukemia Research|July 19, 2011
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinibSimona Soverini, Alessandra Gnani, Caterina De Benedittis, et al.
Leukemia & Lymphoma|January 7, 2009
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term resultsFrancesca Palandri, Nicoletta Testoni, Simona Luatti, et al.
Microorganisms|December 29, 2020
Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant <i>Pseudomonas aeruginosa</i> Infections in Neutropenic PatientsPaolo E Coppola, Paolo Gaibani, Chiara Sartor, et al.
Pageof 16

Showing results (41-50 of 158) with videos related to

Sort By:
Pageof 16
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 22, 2013
Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemiaMario Arpinati, Giulia Tolomelli, Maria Teresa Bochicchio, et al.
Mycoses|September 6, 2017
Successful treatment of bilateral endogenous Fusarium solani endophthalmitis in a patient with acute lymphocytic leukaemiaIlaria Rizzello, Fausto Castagnetti, Pier Giorgio Toschi, et al.
Cells|July 14, 2023
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel InsightsMiriam Iezza, Sofia Cortesi, Emanuela Ottaviani, et al.
Plos One|July 7, 2015
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid LeukemiaManuela Mancini, Elisa Leo, Ken-Ichi Takemaru, et al.
Journal of Cancer Research and Clinical Oncology|January 14, 2017
No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinibMarkus Pfirrmann, Dobromira Evtimova, Susanne Saussele, et al.
Frontiers in Oncology|August 22, 2022
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitorsManuela Mancini, Sara De Santis, Cecilia Monaldi, et al.
Hematological Oncology|January 29, 2020
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axisManuela Mancini, Sara De Santis, Cecilia Monaldi, et al.
Leukemia Research|July 19, 2011
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinibSimona Soverini, Alessandra Gnani, Caterina De Benedittis, et al.
Leukemia & Lymphoma|January 7, 2009
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term resultsFrancesca Palandri, Nicoletta Testoni, Simona Luatti, et al.
Microorganisms|December 29, 2020
Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant <i>Pseudomonas aeruginosa</i> Infections in Neutropenic PatientsPaolo E Coppola, Paolo Gaibani, Chiara Sartor, et al.
Pageof 16